News Daily News Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Michael O'Riordan July 31, 2025
News Daily News No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits Michael O'Riordan July 14, 2025
News Daily News Trade-offs With Invasive Strategy in Older Patients With ACS: Meta-analysis Michael O'Riordan July 03, 2025
News Daily News Private Equity-Backed Hospitals Appear to 'Cherry-Pick' HF Patients Michael O'Riordan June 16, 2025
News Daily News FDA Approves Triple Therapy Polypill for High Blood Pressure Michael O'Riordan June 10, 2025
News Daily News Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION Michael O'Riordan June 04, 2025
News Conference News EuroPCR 2025 ‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI Michael O'Riordan May 29, 2025
News Conference News EuroPCR 2025 Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI Michael O'Riordan May 20, 2025
News Conference News European Congress on Obesity 2025 SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly Michael O'Riordan May 14, 2025
News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Conference News ACC 2025 RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI Michael O'Riordan April 02, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients Michael O'Riordan March 26, 2025
News Daily News REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF Michael O'Riordan March 11, 2025
News Daily News Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD Michael O'Riordan March 06, 2025
News Daily News Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA Michael O'Riordan February 24, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025